This novel method produced medicines that are capable of sustaining therapeutic drug levels for a minimum of 24 h, facilitating once-weekly administration for the majority of these drugs (Holst 2019)
Importantly, AOD-9604 does not bind to growth hormone receptors, which is why it lacks the glucose-elevating and IGF-1-stimulating effects of full-length growth hormone
Epub 2014 Sep 3
The synergy between the two pathways is what makes the combination dosing more efficient per unit of compound
Dose: 0.25mg daily for weeks 1-2, increased to 0.5mg daily for weeks 3-6 Administration: Subcutaneous injection, rotating between deltoid area and upper chest near the shoulder Duration: 6 weeks total Supporting therapy: Light stretching daily, avoided overhead movements until week 4 Three months out from finishing the protocol, my shoulder still feels solid
Semaglutide is a GLP-1 receptor agonist, originally FDA approved in 2020 for type 2 Diabetes under the brand name Ozempic